Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escitalopram + quetiapine
- Development stage
- Unknown
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of escitalopram, a selective serotonin reuptake inhibitor (SSRI), and quetiapine, an atypical antipsychotic. This combination is primarily used in the treatment of depressive episodes in bipolar disorder. Clinical studies have shown that the combination can be more effective than quetiapine alone in improving depressive symptoms, inhibiting inflammatory responses, and regulating oxidative stress without increasing the risk of mania.
02
Targets
HTR2A (5-hydroxytryptamine receptor 2A)SERT (Sodium-dependent serotonin transporter)HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on escitalopram + quetiapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escitalopram + quetiapine.